Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation Shahid I. Sheikh, Frederick R. Long, Karen.

Slides:

Advertisements

Similar presentations

Long-term non-invasive ventilation in cystic fibrosis — Experience over two decades William G. Flight, Jonathan Shaw, Susan Johnson, A. Kevin Webb, Andrew.

Advertisements

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

The prevalence of “risky behaviour” in adults with cystic fibrosis

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Scott D. Sagel, Marci K. Sontag, Meg M

Katarine Egressy, Michaelene Jansen, Keith C. Meyer

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Successful treatment of cepacia syndrome

HRCT and MRI of the lung in children with cystic fibrosis: Comparison of different scoring systems Chiara Sileo, Harriet Corvol, Pierre-Yves Boelle,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection Marita Gilljam, Henrik Scherstén, Martin Silverborn, Bodil.

The ease of breathing test tracks clinical changes in cystic fibrosis

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial S.K. Kabra, R. Pawaiya, Rakesh Lodha,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Clinical presentation of mild cystic fibrosis in a Serbian patient homozygous for the CFTR mutation c G>A Aleksandra Nikolic, Nedeljko Radlovic,

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

Amyloidosis in cystic fibrosis: A case series

Kellie J. Goodlet, Michael D. Nailor, Ashraf Omar, Jasmine L

A.H. Gifford Journal of Cystic Fibrosis

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Cystic fibrosis related diabetes in an extremely young patient

Elisabeth P. Dellon, Elaine Chen, Jessica Goggin, Karen Homa, Bruce C

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy G. Fitch, K. Williams,

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

L. Uppaluri, S.J. England, T.F. Scanlin Journal of Cystic Fibrosis

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Cystic fibrosis and pregnancy in the modern era: A case control study

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation Shahid I. Sheikh, Frederick R. Long, Karen S. McCoy, Terri Johnson, Nancy A. Ryan-Wenger, Don Hayes Journal of Cystic Fibrosis Volume 14, Issue 1, Pages 84-89 (January 2015) DOI: 10.1016/j.jcf.2014.06.011 Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Change in mean modified Brody scores after one year of ivacaftor therapy. Journal of Cystic Fibrosis 2015 14, 84-89DOI: (10.1016/j.jcf.2014.06.011) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Change in mean total modified Brody scores in individual patients after one year of ivacaftor therapy. Journal of Cystic Fibrosis 2015 14, 84-89DOI: (10.1016/j.jcf.2014.06.011) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Alterations in mucus plugging on high resolution computed tomography imaging of the chest comparing images at baseline and then one year after ivacaftor therapy. Journal of Cystic Fibrosis 2015 14, 84-89DOI: (10.1016/j.jcf.2014.06.011) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Alterations in bronchiectasis on high resolution computed tomography imaging of the chest comparing images at baseline and then one year after ivacaftor therapy. Journal of Cystic Fibrosis 2015 14, 84-89DOI: (10.1016/j.jcf.2014.06.011) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 5 Alterations in airway wall thickening on high resolution computed tomography imaging of the chest comparing images at baseline and then one year after ivacaftor therapy. Journal of Cystic Fibrosis 2015 14, 84-89DOI: (10.1016/j.jcf.2014.06.011) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions